Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02565511 · ClinicalTrials.gov registry record · Phase 2
A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 480
- Enrollment target
NCT02565511: Clinical Trial Phase 2 study, sponsored by Novartis Pharmaceuticals.
NCT02565511 is a Phase 2 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 480 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (261% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02565511, a Phase 2 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 480 participants
- Enrollment target
Study Summary
The purpose of this study was to test whether two investigational drugs called CAD106 and CNP520, administered separately, could slow down the onset and progression of clinical symptoms associated with Alzheimer's disease (AD) in participants at the risk to develop clinical symptoms based on their age and genotype.
Primary Outcome
Event was defined as the first confirmed diagnosis of MCI due to Alzheimer's disease (AD) or dementia due to AD (whichever occurred first) after adjudication by the progression adjudication committee (PAC) as triggered either by an investigator diagnosis or an increase in the Clinical Dementia Rating (CDR) global score. An event had to be confirmed by the PAC at two consecutive visits. In case no confirmed event was observed for a participant, the observation was censored, and the censoring date
Interventions
- DRUG CNP520
- BIOLOGICAL CAD106 Immunotherapy
- OTHER Placebo to CAD106
- OTHER Placebo to CNP520
- OTHER Alum
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 480 participants |
| Start Date | 2015-11-30 |
| Est. Completion | 2020-04-30 |
| Phase | Phase 2 |
Why NCT02565511 stopped before completion
NCT02565511 is an interventional study that assigns participants to a tested intervention. The registered 480 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (261% higher).
The record links to 0 conditions, and to 5 interventions - of which CNP520 is the first listed.
NCT02565511 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02565511 about?
NCT02565511 is a clinical study titled "A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease". The purpose of this study was to test whether two investigational drugs called CAD106 and CNP520, administered separately, could slow down the onset and progression of clinical symptoms associated with Alzheimer's disease (AD) in participants at the risk to develop clinical symptoms based on their a...
What is the current status of trial NCT02565511?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 480 participants. The study started on 2015-11-30. Estimated completion is 2020-04-30.
What interventions are being tested in trial NCT02565511?
The interventions under investigation include: CNP520 (DRUG), CAD106 Immunotherapy (BIOLOGICAL), Placebo to CAD106 (OTHER), Placebo to CNP520 (OTHER), Alum (OTHER).
Who is sponsoring clinical trial NCT02565511?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02565511's enrollment target sits among peer trials
480 76th of 2000 higher than 1,924 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01954992 · 480 participants · Phase 3
Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
- NCT03023696 · 480 participants · NA
Can Prophylactic Foraminotomy Prevent C5 Palsy
- NCT04948060 · 480 participants · NA
Tribally Engaged Approaches to Lung Screening (TEALS)
- NCT05053230 · 480 participants · NA
A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI